TY - JOUR PY - 2023// TI - Pilot test of intranasal oxytocin as an enhancer of brief couples therapy for posttraumatic stress disorder JO - Journal of psychiatric research A1 - Sippel, Lauren M. A1 - Khalifian, Chandra E. A1 - Knopp, Kayla C. A1 - Webster, Katelyn A1 - Maglione, Jeanne A1 - Holcomb, Julie A1 - Flanagan, Julianne C. A1 - Monson, Candice M. A1 - Holtzheimer, Paul E. A1 - Morland, Leslie A. SP - 165 EP - 169 VL - 161 IS - N2 - Posttraumatic stress disorder (PTSD) negatively impacts military veterans and their intimate partners. Cognitive-Behavioral Conjoint Therapy (CBCT) was developed to address both PTSD and relationship satisfaction among couples. Although efficacious in improving PTSD, the effects of CBCT and the 8-session brief CBCT (bCBCT) on relationship satisfaction among veteran patients with PTSD are modest. Pharmacological augmentation with the neuropeptide oxytocin is promising for enhancing bCBCT's potency due to its effects on mechanisms of trauma recovery (e.g., extinction learning) and relationship functioning (e.g., trust, communication). The goal of this pilot uncontrolled clinical trial was to examine the feasibility and preliminary efficacy of bCBCT augmented with intranasal oxytocin for improving PTSD and relationship satisfaction among 10 U.S. veterans with PTSD and their intimate partners. Veterans self-administered 40 international units of intranasal oxytocin 30 min before each bCBCT session delivered to the couple via telehealth. Both partners completed pre-assessment, weekly, post, and 3-month follow-up assessments of PTSD symptoms and relationship satisfaction. Couples also provided qualitative feedback related to feasibility and engagement. Nine dyads completed the treatment. There were no serious adverse events. Veterans and partners reported moderate to large effect size improvements in relationship satisfaction (Hedge's g = 0.55 and 1.01, respectively). Veterans reported large effect size reductions in PTSD severity (Hedge's g = 1.87). These results suggest that virtual oxytocin-assisted bCBCT is feasible, scalable, potentially efficacious, and should be tested with a placebo-controlled randomized controlled trial.

Language: en

LA - en SN - 0022-3956 UR - http://dx.doi.org/10.1016/j.jpsychires.2023.03.001 ID - ref1 ER -